acquired
Stage
About
Arthrosi is a clinical-stage biotech company developing AR882, a novel therapy targeting gout and chronic kidney disease with demonstrated sustained urate lowering and potential to treat gout patients with renal impairment.
Explore Arthrosi's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.